A Non-Interventional Survey Study on the Preferences of Patients with AtrialFibrillation and Physicians Treating Atrial Fibrillation for Anticoagulant Treatment Outcomes
Study on Preferences for Anticoagulant Treatment in Atrial Fibrillation
Michael Moran, MD
Primary Investigator
Brief description of study
To identify the relative importance of attributes of anticoagulant treatment to AF patients and physicians that treat AF patients To quantify the tradeoffs that patients and physicians are willing to make between attributes associated with anticoagulant treatment.
Detailed description of study
- Participants will be asked to complete a survey during an in-person study visit on the same electronic tablet that is also used for the LIBREXIA AF study.
- The survey will take about 30 minutes to complete.
Eligibility of study
You may be eligible for this study if you meet the following criteria:
- Conditions: Atrial fibrillation., AF
-
Age: 18 years - 100 years
-
Gender: All
Inclusion criteria:
- Patients with AF enrolled at US sites in the LIBREXIA AF Phase 3 study
This study investigates the preferences of patients with atrial fibrillation (AF) and the doctors who treat them regarding anticoagulant treatments. Atrial fibrillation is a condition where the heart beats irregularly, which can lead to blood clots, stroke, and heart failure. The purpose is to understand what features of anticoagulant treatments are most important to both patients and doctors.
Participants will complete a survey during an in-person visit using an electronic tablet. The survey is designed to take about 30 minutes. This study does not change any treatments participants are receiving.
- Who can participate: Only patients with atrial fibrillation who are part of the LIBREXIA AF Phase 3 study at US sites can participate.
- Study details: Participants will fill out a survey on an electronic tablet.
